Agenus Inc. (AGEN)
Healthcare · Biotechnology · NASDAQ · US
$7.67+1.72%Close
SELLCRISIS · day 4
$7.67+1.72%
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $319M
- Beta
- 1.55
- P/E (TTM)
- 2.76
- Short % float
- 18.33%
- Days to cover
- 5.7
- SI change
- +0.2%
- 1W
- -8.25%
- 1M
- +11.32%
- vs SPY 1W
- -9.41%
- vs SPY 1M
- +8.33%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey
Agenus (NASDAQ:AGEN) Stock Keeps “Buy” Rating at Chardan Capital
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Here’s Why
Agenus to Participate in Upcoming September Investor Conferences
Agenus to Participate in Upcoming September Investor Conferences
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Agenus to Provide Second Quarter 2026 Financial Report and Development Update